271 related articles for article (PubMed ID: 25931315)
1. Feasibility and safety of dose-dense modified docetaxel-cisplatin or carboplatin and 5-fluorouracil regimen (mTPF) in locally advanced or metastatic head and neck cancers: a retrospective monocentric study.
Yossi S; Linot B; Peyraga G; Breheret R; Laccourreye L; Capitain O
Int J Clin Oncol; 2015 Dec; 20(6):1086-92. PubMed ID: 25931315
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy with modified docetaxel, cisplatin, and 5-fluorouracil in patients with metastatic head and neck cancer.
Lin JT; Lai GM; Chang TH; Liu MT; Bi CP; Wang JW; Chen MK
Adv Ther; 2012 Jan; 29(1):71-7. PubMed ID: 22161550
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy with docetaxel, cisplatin, fluorouracil and l-leucovorin for locally advanced head and neck cancers: a modified regimen for Japanese patients.
Watanabe A; Taniguchi M; Sasaki S
Anticancer Drugs; 2003 Nov; 14(10):801-7. PubMed ID: 14597874
[TBL] [Abstract][Full Text] [Related]
4. Dose-dense TPF induction chemotherapy for locally advanced head and neck cancer: a phase II study.
Hsieh CY; Lein MY; Yang SN; Wang YC; Lin YJ; Lin CY; Hua CH; Tsai MH; Lin CC
BMC Cancer; 2020 Sep; 20(1):832. PubMed ID: 32873270
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of dose-modified docetaxel plus cisplatin-based induction chemotherapy in Asian patients with locally advanced head and neck cancer.
Huang CE; Lu CH; Chen PT; Chan CH; Chen WC; Wang WH; Wu JY; Kuan FC; Lee KD; Chen CC
J Clin Pharm Ther; 2012 Jun; 37(3):342-7. PubMed ID: 21950487
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.
Tomasello G; Chiesa MD; Buti S; Brighenti M; Negri F; Rovere RK; Martinotti M; Buononato M; Brunelli A; Lazzarelli S; Donati G; Passalacqua R
Tumori; 2010; 96(1):48-53. PubMed ID: 20437857
[TBL] [Abstract][Full Text] [Related]
7. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
[TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial.
Lorch JH; Goloubeva O; Haddad RI; Cullen K; Sarlis N; Tishler R; Tan M; Fasciano J; Sammartino DE; Posner MR;
Lancet Oncol; 2011 Feb; 12(2):153-9. PubMed ID: 21233014
[TBL] [Abstract][Full Text] [Related]
9. Toxicity of induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil for advanced head and neck cancer.
Billan S; Kaidar-Person O; Atrash F; Doweck I; Haim N; Kuten A; Ronen O
Isr Med Assoc J; 2013 May; 15(5):231-5. PubMed ID: 23841243
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study.
Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant modified TPF (docetaxel, cisplatin, fluorouracil) for patients unfit to standard TPF in locally advanced head and neck squamous cell carcinoma: a study of 48 patients.
Fayette J; Fontaine-Delaruelle C; Ambrun A; Daveau C; Poupart M; Ramade A; Zrounba P; Neidhardt EM; Péron J; Diallo A; Céruse P
Oncotarget; 2016 Jun; 7(24):37297-37304. PubMed ID: 27119503
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled phase II comparison study of concurrent chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil versus CCRT with cisplatin, 5-fluorouracil, methotrexate and leucovorin in patients with locally advanced squamous cell carcinoma of the head and neck.
Tsukuda M; Ishitoya J; Matsuda H; Horiuchi C; Taguchi T; Takahashi M; Nishimura G; Kawakami M; Watanabe M; Niho T; Kawano T; Ikeda Y; Sakuma Y; Shiono O; Komatsu M
Cancer Chemother Pharmacol; 2010 Sep; 66(4):729-36. PubMed ID: 20033810
[TBL] [Abstract][Full Text] [Related]
13. Taxane, platinum and 5-FU prior to chemoradiotherapy benefits patients with stage IV neck node-positive head and neck cancer and a good performance status.
Lowe NM; Bernstein JM; Mais K; Garcez K; Lee LW; Sykes A; Thomson DJ; Homer JJ; West CM; Slevin NJ
J Cancer Res Clin Oncol; 2018 Feb; 144(2):389-401. PubMed ID: 29222650
[TBL] [Abstract][Full Text] [Related]
14. Comparison of carboplatin-paclitaxel to docetaxel-cisplatin-5-flurouracil induction chemotherapy followed by concurrent chemoradiation for locally advanced head and neck cancer.
Herman LC; Chen L; Garnett A; Feldman LE; Smith B; Weichselbaum RR; Spiotto MT
Oral Oncol; 2014 Jan; 50(1):52-8. PubMed ID: 24055193
[TBL] [Abstract][Full Text] [Related]
15. A phase I study of cabazitaxel in combination with platinum and 5-fluorouracil (PF) in locally advanced squamous cell carcinoma of head and neck (LA-SCCHN).
Camille N; Rozehnal J; Roy E; Uczkowski D; Olson A; Genden E; Teng M; Bakst R; Gupta V; Posner M; Misiukiewicz K
Oral Oncol; 2017 Aug; 71():99-104. PubMed ID: 28688700
[TBL] [Abstract][Full Text] [Related]
16. TPF plus cetuximab induction chemotherapy followed by biochemoradiation with weekly cetuximab plus weekly cisplatin or carboplatin: a randomized phase II EORTC trial.
Specenier PM; Remenar E; Buter J; Schrijvers DL; Bergamini C; Licitra LF; Awada A; Clement PM; Fortpied C; Menis J; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2219-2224. PubMed ID: 28911062
[TBL] [Abstract][Full Text] [Related]
17. Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trial.
Dalla Chiesa M; Tomasello G; Buti S; Rovere RK; Brighenti M; Lazzarelli S; Donati G; Passalacqua R
Cancer Chemother Pharmacol; 2011 Jan; 67(1):41-8. PubMed ID: 20204366
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel, cisplatin, and fluorouracil for patients with inoperable recurrent or metastatic head and neck squamous cell carcinoma.
Cho H; Nishiike S; Yamamoto Y; Takenaka Y; Nakahara S; Yasui T; Hanamoto A; Inohara H
Auris Nasus Larynx; 2015 Oct; 42(5):396-400. PubMed ID: 25721854
[TBL] [Abstract][Full Text] [Related]
19. Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas.
Prestwich RJ; Öksüz DÇ; Dyker K; Coyle C; Şen M
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):e237-43. PubMed ID: 21620580
[TBL] [Abstract][Full Text] [Related]
20. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
Vermorken JB; Remenar E; van Herpen C; Gorlia T; Mesia R; Degardin M; Stewart JS; Jelic S; Betka J; Preiss JH; van den Weyngaert D; Awada A; Cupissol D; Kienzer HR; Rey A; Desaunois I; Bernier J; Lefebvre JL;
N Engl J Med; 2007 Oct; 357(17):1695-704. PubMed ID: 17960012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
